<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00564213</url>
  </required_header>
  <id_info>
    <org_study_id>BQ -1-07-ARVO</org_study_id>
    <nct_id>NCT00564213</nct_id>
  </id_info>
  <brief_title>Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefractive Keratectomy for High Myopia: 15 x 30 Seconds</brief_title>
  <acronym>BQ-01-07-ARVO</acronym>
  <official_title>Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefractive Keratectomy for High Myopia: 15 x 30 Seconds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Olhos de Goiania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Olhos de Goiania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate and compare the effect of the prophylactic use of two different exposure times of
      mitomycin C (MMC) 0.02% to inhibit haze formation after photorefractive keratectomy (PRK) for
      high myopia (&gt; -7.0 D).

      Methods: Forty six eyes of twenty three patients, 8 men and 15 women, with high myopia were
      included in this prospective study. Mean age at the time of PRK plus MMC was 31.7 years.
      Before PRK, the mean spherical equivalent was -8.50 D (range, -7.25 to -10.50 D). In each
      patient, one eye was randomly assigned to PRK and a single intraoperative topical application
      of mitomycin C 0.02% for 15 seconds (Group 1) and the fellow eye, for 30 seconds (Group
      2).The inclusion criteria were high myopia, no central corneal opacity and inadequate corneal
      thickness to allow a safe Laser in situ keratomileusis procedure. Refraction, uncorrected
      visual acuity, best spectacle-corrected visual acuity (BSCVA), and slit-lamp evidence of
      corneal opacity (haze) were evaluated over 12 months
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>High Myopia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single intraoperative topical application of mitomycin C 0.02% for 15 seconds</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single intraoperative topical application of mitomycin C 0.02% for 30 seconds</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds</intervention_name>
    <description>Mitomycin 0.02%</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Myopia or compound myopic astigmatism

          -  Stable refractive error

          -  No associated eye disease

        Exclusion Criteria:

          -  Diabetes,

          -  Autoimmune diseases

          -  Topographic abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Belquiz A Nassaralla</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto de Olhos de GOi√¢nia</affiliation>
  </overall_official>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2007</study_first_submitted>
  <study_first_submitted_qc>November 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2007</study_first_posted>
  <last_update_submitted>November 25, 2008</last_update_submitted>
  <last_update_submitted_qc>November 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2008</last_update_posted>
  <keyword>Myopia</keyword>
  <keyword>Mitomycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

